|
NZ700362A
(en)
*
|
2012-04-11 |
2016-09-30 |
Us Health |
Chimeric antigen receptors targeting b-cell maturation antigen
|
|
WO2014100615A1
(en)
|
2012-12-20 |
2014-06-26 |
Purdue Research Foundation |
Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
|
|
EP2948544A4
(en)
|
2013-01-28 |
2016-08-03 |
St Jude Childrens Res Hospital |
CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
|
|
CN103965361B
(zh)
*
|
2013-02-06 |
2018-10-30 |
上海细胞治疗工程技术研究中心集团有限公司 |
一种t细胞信号的嵌合分子转换器及其用途
|
|
US9657105B2
(en)
|
2013-03-15 |
2017-05-23 |
City Of Hope |
CD123-specific chimeric antigen receptor redirected T cells and methods of their use
|
|
ES2769574T3
(es)
|
2013-03-15 |
2020-06-26 |
Michael C Milone |
Reconocimiento de células citotóxicas con receptores quiméricos para inmunoterapia adoptiva
|
|
CN104072616A
(zh)
*
|
2013-03-29 |
2014-10-01 |
上海中信国健药业股份有限公司 |
一种嵌合受体及其制备方法和用途
|
|
KR102098985B1
(ko)
*
|
2013-05-03 |
2020-04-09 |
오하이오 스테이트 이노베이션 파운데이션 |
Cs1-특이적 키메라 항원 수용체 가공된 면역 작동체 세포
|
|
AU2014262469B2
(en)
|
2013-05-10 |
2019-11-14 |
Whitehead Institute For Biomedical Research |
Protein modification of living cells using sortase
|
|
KR102271498B1
(ko)
|
2013-08-30 |
2021-07-05 |
보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 |
종양 치료를 위한 키누레닌 고갈 효소의 투여
|
|
CN105829349B
(zh)
*
|
2013-10-15 |
2023-02-03 |
斯克利普斯研究所 |
肽嵌合抗原受体t细胞开关和其用途
|
|
US10144770B2
(en)
|
2013-10-17 |
2018-12-04 |
National University Of Singapore |
Chimeric receptors and uses thereof in immune therapy
|
|
MX377283B
(es)
*
|
2013-11-21 |
2025-03-07 |
Ucl Business Ltd |
Célula t o nk que coexpresa un receptor antigénico quimérico (car).
|
|
EP4420663A3
(en)
|
2013-12-20 |
2024-10-30 |
Novartis AG |
Regulatable chimeric antigen receptor
|
|
AU2014376328A1
(en)
*
|
2014-01-13 |
2016-07-21 |
Christine E. BROWN |
Chimeric antigen receptors (CARs) having mutations in the Fc spacer region and methods for their use
|
|
GB201405845D0
(en)
|
2014-04-01 |
2014-05-14 |
Ucl Business Plc |
Signalling system
|
|
CA2942459C
(en)
*
|
2014-04-01 |
2023-03-07 |
Biontech Cell & Gene Therapies Gmbh |
Claudin-6-specific immunoreceptors and t cell epitopes
|
|
KR102508166B1
(ko)
|
2014-04-10 |
2023-03-13 |
시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 |
세포 면역요법을 위한 방법 및 조성물
|
|
AU2015259877B2
(en)
|
2014-05-15 |
2021-02-25 |
National University Of Singapore |
Modified natural killer cells and uses thereof
|
|
JP2017525385A
(ja)
|
2014-06-18 |
2017-09-07 |
ケモテラペウティシェス フォルシュングインスティトゥート ゲオルグ−シュパイヤー−ハウス |
細胞治療物質としてのｃａｒ発現ｎｋ−９２細胞
|
|
KR102612313B1
(ko)
|
2014-07-21 |
2023-12-12 |
노파르티스 아게 |
인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
|
|
KR102818922B1
(ko)
|
2014-08-28 |
2025-06-11 |
바이오아트라, 인코퍼레이티드 |
변형된 t 세포에 대한 조건부 활성 키메라 항원 수용체
|
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
|
ES2987380T3
(es)
|
2014-08-29 |
2024-11-14 |
Univ Texas |
Administración de enzimas de depleción de la quinurenina para la terapia tumoral
|
|
BR112017005390A2
(pt)
|
2014-09-17 |
2017-12-12 |
Novartis Ag |
células citotóxicas alvo com receptores quiméricos para imunoterapia adotiva
|
|
CA2964317C
(en)
|
2014-10-14 |
2021-10-05 |
Halozyme, Inc. |
Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
|
|
US10570186B2
(en)
|
2014-11-05 |
2020-02-25 |
Board Of Regents, The University Of Texas System |
Chimeric antigen receptors (CAR) to selectively target protein complexes
|
|
US20180148480A1
(en)
*
|
2015-01-16 |
2018-05-31 |
The Johns Hopkins University |
Synthetic enhancement of the t-cell armamentarium as an anti-cancer therapy
|
|
US20180002427A1
(en)
|
2015-01-26 |
2018-01-04 |
Cellectis |
Cll1-specific multi-chain chimeric antigen receptor
|
|
GB201501936D0
(en)
*
|
2015-02-05 |
2015-03-25 |
Ucl Business Plc |
Signalling system
|
|
EP3256490A1
(en)
|
2015-02-09 |
2017-12-20 |
Research Development Foundation |
Engineered immunoglobulin fc polypeptides displaying improved complement activation
|
|
US20170151281A1
(en)
*
|
2015-02-19 |
2017-06-01 |
Batu Biologics, Inc. |
Chimeric antigen receptor dendritic cell (car-dc) for treatment of cancer
|
|
CN107530424A
(zh)
|
2015-02-20 |
2018-01-02 |
俄亥俄州国家创新基金会 |
针对nkg2d和肿瘤相关抗原的二价抗体
|
|
WO2016135291A1
(en)
*
|
2015-02-26 |
2016-09-01 |
Var2 Pharmaceuticals Aps |
Immunotherapeutic targeting of placental-like chondroitin sulfate using chimeric antigen receptors (cars) and immunotherapeutic targeting of cancer using cars with split-protein binding systems
|
|
US10800828B2
(en)
|
2015-03-26 |
2020-10-13 |
The Scripps Research Institute |
Switchable non-scFv chimeric receptors, switches, and methods of use thereof to treat cancer
|
|
JP6879932B2
(ja)
|
2015-04-06 |
2021-06-02 |
サイトイミューン セラピューティクス， インコーポレイテッドＣｙｔｏｉｍｍｕｎｅ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｌｃ |
神経膠芽腫のためのｅｇｆｒ指向ｃａｒ療法
|
|
EP3283113A4
(en)
|
2015-04-15 |
2018-12-05 |
The California Institute for Biomedical Research |
Optimized pne-based chimeric receptor t cell switches and uses thereof
|
|
PT3286223T
(pt)
|
2015-04-23 |
2024-03-22 |
HaemaLogiX Ltd |
Recetores de antigénio quimérico do antigénio do mieloma kappa e suas utilizações
|
|
CN107709552B
(zh)
|
2015-06-10 |
2022-05-13 |
南克维斯特公司 |
用于治疗癌症的修饰的nk-92细胞
|
|
US10166255B2
(en)
*
|
2015-07-31 |
2019-01-01 |
Regents Of The University Of Minnesota |
Intracellular genomic transplant and methods of therapy
|
|
CN108350062B
(zh)
*
|
2015-08-06 |
2022-10-14 |
达纳-法伯癌症研究所股份有限公司 |
靶向蛋白降解以减弱过继性t细胞疗法相关的不良炎症反应
|
|
US11458167B2
(en)
|
2015-08-07 |
2022-10-04 |
Seattle Children's Hospital |
Bispecific CAR T-cells for solid tumor targeting
|
|
US10526408B2
(en)
|
2015-08-28 |
2020-01-07 |
Research Development Foundation |
Engineered antibody FC variants
|
|
MA44907A
(fr)
*
|
2015-09-11 |
2018-07-18 |
Agenus Inc |
Cellules hôtes génétiquement modifiées et leurs procédés d'utilisation
|
|
GB201518136D0
(en)
*
|
2015-10-14 |
2015-11-25 |
Glaxosmithkline Ip Dev Ltd |
Novel chimeric antigen receptors
|
|
MY189819A
(en)
|
2015-11-27 |
2022-03-10 |
Cartherics Pty Ltd |
Genetically modified cells and uses thereof
|
|
WO2017151860A1
(en)
|
2016-03-02 |
2017-09-08 |
Broard Of Regents, The University Of Texas System |
Human kynureninase enzyme variants having improved pharmacological properties
|
|
UA128781C2
(uk)
|
2016-04-01 |
2024-10-23 |
Кайт Фарма, Інк. |
Т-клітина, спосіб її отримання та застосування
|
|
KR102522622B1
(ko)
|
2016-04-01 |
2023-04-18 |
카이트 파마 인코포레이티드 |
Bcma 결합 분자 및 그의 사용 방법
|
|
CU20180121A7
(es)
|
2016-04-01 |
2019-05-03 |
Kite Pharma Inc |
Receptores de antígenos quiméricos y células t
|
|
EP3439675A4
(en)
|
2016-04-08 |
2019-12-18 |
Purdue Research Foundation |
METHOD AND COMPOSITIONS FOR CAR-T CELL THERAPY
|
|
EP3443096B1
(en)
*
|
2016-04-15 |
2023-03-01 |
Novartis AG |
Compositions and methods for selective expression of chimeric antigen receptors
|
|
WO2017197234A1
(en)
|
2016-05-13 |
2017-11-16 |
Bioatla, Llc |
Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereof
|
|
CN110035768A
(zh)
|
2016-07-26 |
2019-07-19 |
泰莎治疗私人有限公司 |
嵌合抗原受体
|
|
EP3519562A4
(en)
|
2016-09-29 |
2020-03-25 |
Nantkwest, Inc. |
NK-92 HLA CLASS I DEFICIENT CELLS WITH REDUCED IMMUNOGENICITY
|
|
MX2019004181A
(es)
|
2016-10-13 |
2019-10-30 |
Juno Therapeutics Inc |
Métodos y composiciones de inmunoterapia que implican moduladores de la ruta metabólica de triptófano.
|
|
CA3040343A1
(en)
|
2016-10-19 |
2018-04-26 |
California Institute For Biomedical Research |
Chimeric antigen receptor effector cell switches with humanized targeting moieties and/or optimized chimeric antigen receptor interacting domains and uses thereof
|
|
KR102630036B1
(ko)
|
2016-12-23 |
2024-01-29 |
마크로제닉스, 인크. |
Adam9-결합 분자, 및 이것의 사용 방법
|
|
WO2018129346A1
(en)
|
2017-01-06 |
2018-07-12 |
Nantkwest, Inc. |
Genetically modified nk-92 cells with decreased cd96/tigit expression
|
|
EP3579870A4
(en)
|
2017-02-07 |
2020-12-30 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
PHOSPHOLIPID ETHER (PLE) T CAR-LYMPHOCYTE TUMOR (CTCT) TARGETING AGENTS
|
|
AU2018219289A1
(en)
|
2017-02-08 |
2019-09-05 |
Dana-Farber Cancer Institute, Inc. |
Regulating chimeric antigen receptors
|
|
CN110582288B
(zh)
|
2017-02-28 |
2024-09-20 |
恩多塞特公司 |
用于car t细胞疗法的组合物和方法
|
|
CN117384929A
(zh)
|
2017-03-27 |
2024-01-12 |
新加坡国立大学 |
一种编码由细胞表达的嵌合受体的多核苷酸
|
|
RU2019128544A
(ru)
|
2017-03-27 |
2021-04-28 |
Нэшнл Юниверсити Оф Сингапур |
Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров
|
|
KR20240059648A
(ko)
|
2017-04-19 |
2024-05-07 |
더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 |
조작된 항원 수용체를 발현하는 면역 세포
|
|
WO2018232372A1
(en)
*
|
2017-06-16 |
2018-12-20 |
Protelica, Inc. |
Fibronectin binding domain chimeric antigen receptors and methods of use thereof
|
|
EP3645036A1
(en)
|
2017-06-30 |
2020-05-06 |
Cellectis |
Cellular immunotherapy for repetitive administration
|
|
JP2021500882A
(ja)
*
|
2017-10-18 |
2021-01-14 |
プレシゲン，インコーポレイテッド |
スペーサーを含むポリペプチド組成物
|
|
WO2019084284A1
(en)
|
2017-10-27 |
2019-05-02 |
Coneksis, Inc. |
NK CELLS FOR USE IN THE TREATMENT OF CANCER IN DOGS
|
|
US11760806B2
(en)
|
2017-11-03 |
2023-09-19 |
Sorrento Therapeutics, Inc. |
CD-38 directed chimeric antigen receptor constructs
|
|
US11390655B2
(en)
|
2017-11-16 |
2022-07-19 |
Kite Pharma, Inc. |
Modified chimeric antigen receptors and methods of use
|
|
CN112055595B
(zh)
|
2018-01-22 |
2024-12-17 |
恩多塞特公司 |
Car t细胞的使用方法
|
|
WO2019144707A1
(zh)
*
|
2018-01-26 |
2019-08-01 |
重庆精准生物技术有限公司 |
一种改良的铰链区及其在构建car骨架中的应用
|
|
US20210040451A1
(en)
|
2018-01-31 |
2021-02-11 |
Nantkwest, Inc. |
Use of 5% human albumin in wash and harvest media
|
|
CA3090089A1
(en)
|
2018-02-06 |
2019-08-15 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
|
|
AU2019219454A1
(en)
|
2018-02-09 |
2020-08-27 |
National University Of Singapore |
Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
|
|
CN111918661A
(zh)
|
2018-02-21 |
2020-11-10 |
得克萨斯大学体系董事会 |
用于活化和扩增自然杀伤细胞的方法及其用途
|
|
JP7568224B2
(ja)
|
2018-02-23 |
2024-10-16 |
エンドサイト・インコーポレイテッド |
Ｃａｒ ｔ細胞療法のための配列決定法
|
|
MX2020009272A
(es)
|
2018-03-06 |
2021-01-08 |
Univ Pennsylvania |
Receptores de antígeno quimérico del antígeno de membrana específico de próstata y métodos de uso de los mismos.
|
|
CN112004829A
(zh)
|
2018-03-12 |
2020-11-27 |
南克维斯特公司 |
Cd33car修饰的高亲和力nk细胞(t-hank)用于降低髓系衍生的抑制细胞的抑制活性(或降低对nk细胞活性的负面影响)的用途
|
|
JP7334985B2
(ja)
|
2018-04-02 |
2023-08-29 |
ナショナル ユニヴァーシティー オブ シンガポール |
免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
|
|
TWI827593B
(zh)
|
2018-04-16 |
2024-01-01 |
美國德州系統大學評議委員會 |
人類犬尿胺酸酶及其用途
|
|
US20210238255A1
(en)
|
2018-04-23 |
2021-08-05 |
Baylor College Of Medicine |
Chimeric hla accessory receptor
|
|
SG11202010451QA
(en)
*
|
2018-05-21 |
2020-11-27 |
Biosceptre Uk Ltd |
Chimeric antigen receptors with modified linker domains and uses thereof
|
|
IL321548A
(en)
|
2018-05-22 |
2025-08-01 |
Immunitybio Inc |
Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
|
|
JP7208262B2
(ja)
|
2018-05-22 |
2023-01-18 |
イミュニティーバイオ インコーポレイテッド |
ポロキサマーを用いてｎｋ－９２細胞増殖を最適化する方法
|
|
KR20210011977A
(ko)
|
2018-05-22 |
2021-02-02 |
난트케이웨스트, 인크. |
Nk-92 세포를 성장시키기 위한 기초 배지
|
|
EP3806962A1
(en)
|
2018-06-13 |
2021-04-21 |
Novartis AG |
Bcma chimeric antigen receptors and uses thereof
|
|
KR102721222B1
(ko)
|
2018-07-10 |
2024-10-24 |
이뮤너티바이오, 인크. |
제대혈로부터 cik nkt 세포의 생성
|
|
US20210267190A1
(en)
|
2018-07-10 |
2021-09-02 |
Nantkwest, Inc. |
Cryopreservation
|
|
WO2020028654A1
(en)
|
2018-08-01 |
2020-02-06 |
Nantkwest, Inc. |
Combined invasion and cytotoxicity assay using chemokine secreting target cells
|
|
CN113164519B
(zh)
|
2018-08-01 |
2025-01-10 |
南克维斯特公司 |
用于免疫疗法的基因修饰的包含归巢受体或细胞因子和嵌合抗原受体的四顺反子系统
|
|
EP3830113A1
(en)
|
2018-08-01 |
2021-06-09 |
Nantkwest, Inc. |
Chemokine responsive activated natural killer cells with secondary homing activation for verified targets
|
|
EP3844186A4
(en)
|
2018-08-29 |
2022-08-17 |
National University of Singapore |
METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
|
|
US12109238B2
(en)
|
2018-11-06 |
2024-10-08 |
Immunitybio, Inc. |
Chimeric antigen receptor-modified NK-92 cells
|
|
IL316887A
(en)
|
2018-11-06 |
2025-01-01 |
Immunitybio Inc |
NK-92 cells with chimeric antigen receptor modification
|
|
CA3117936A1
(en)
|
2018-11-26 |
2020-06-04 |
Immunitybio, Inc. |
Il-2 dependent nk-92 cells with stable fc receptor expression
|
|
EP3773918A4
(en)
|
2019-03-05 |
2022-01-05 |
Nkarta, Inc. |
ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
|
|
US20220184128A1
(en)
*
|
2019-03-28 |
2022-06-16 |
Korea Research Institute Of Bioscience And Biotechnology |
Method for producing car gene-introduced nk cells and use thereof
|
|
TW202110873A
(zh)
|
2019-04-30 |
2021-03-16 |
美商聖堤生物科技股份有限公司 |
嵌合受體及其使用方法
|
|
TWI872076B
(zh)
|
2019-05-27 |
2025-02-11 |
美商英麥提克斯股份有限公司 |
病毒載體及其在授受性細胞療法之應用
|
|
WO2021021213A1
(en)
|
2019-08-01 |
2021-02-04 |
Nantkwest, Inc. |
Anti-b7-h4 chimeric antigen receptor-modified nk-92 cells
|
|
KR102287180B1
(ko)
*
|
2019-10-01 |
2021-08-09 |
충북대학교 산학협력단 |
Cd138에 특이적으로 결합하는 키메릭 항원 수용체, 이를 발현하는 면역세포 및 이의 항암 용도
|
|
US20220372125A1
(en)
*
|
2019-10-02 |
2022-11-24 |
Aslan Pharmaceuticals Pte. Ltd. |
Antigen Specific Binding Domains and Antibody Molecules
|
|
EP4491235A3
(en)
*
|
2019-11-26 |
2025-03-26 |
ImmunityBio, Inc. |
Primary nk car constructs and methods
|
|
US10980836B1
(en)
|
2019-12-11 |
2021-04-20 |
Myeloid Therapeutics, Inc. |
Therapeutic cell compositions and methods of manufacturing and use thereof
|
|
KR20220130158A
(ko)
|
2020-01-23 |
2022-09-26 |
더 칠드런스 메디칼 센터 코포레이션 |
인간 만능 줄기 세포로부터의 무-간질 t 세포 분화
|
|
US11230699B2
(en)
|
2020-01-28 |
2022-01-25 |
Immunitybio, Inc. |
Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
|
|
KR102626782B1
(ko)
*
|
2020-02-14 |
2024-01-19 |
주식회사 셀젠텍 |
B세포 성숙화 항원을 표적으로 하는 키메라 항원 수용체 및 이의 용도
|
|
US20240261404A1
(en)
*
|
2020-04-17 |
2024-08-08 |
2Seventy Bio, Inc. |
Modified ccr polypeptides and uses thereof
|
|
WO2021217113A1
(en)
*
|
2020-04-25 |
2021-10-28 |
East Carolina University |
Compositions and methods of treating a coronavirus infection by use of an interferon fusion protein
|
|
WO2021221927A1
(en)
|
2020-04-27 |
2021-11-04 |
Parsons Corporation |
Narrowband iq signal obfuscation
|
|
CA3180613A1
(en)
|
2020-06-05 |
2021-12-09 |
Aung MYO |
Treatment of cd30-positive cancer
|
|
KR102297396B1
(ko)
|
2020-07-29 |
2021-09-06 |
(주)티카로스 |
면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포
|
|
WO2022098756A1
(en)
*
|
2020-11-03 |
2022-05-12 |
WUGEN, Inc. |
Chimeric antigen receptor cell therapy
|
|
WO2022098905A2
(en)
|
2020-11-04 |
2022-05-12 |
Myeloid Therapeutics, Inc. |
Engineered chimeric fusion protein compositions and methods of use thereof
|
|
EP4247850A1
(en)
|
2020-11-20 |
2023-09-27 |
Simcere Innovation, Inc. |
Armed dual car-t compositions and methods for cancer immunotherapy
|
|
CN116782937A
(zh)
|
2020-12-10 |
2023-09-19 |
优特力克斯有限公司 |
抗pd-1抗体及其用途
|
|
CN114716548B
(zh)
|
2021-01-05 |
2024-11-05 |
(株)爱恩德生物 |
抗-fgfr3抗体及其用途
|
|
US12144827B2
(en)
|
2021-02-25 |
2024-11-19 |
Lyell Immunopharma, Inc. |
ROR1 targeting chimeric antigen receptor
|
|
MX2023010916A
(es)
|
2021-03-17 |
2023-12-14 |
Myeloid Therapeutics Inc |
Composiciones de proteinas de fusion quimericas modificadas por ingenieria y metodos de uso de las mismas.
|
|
WO2022232015A1
(en)
*
|
2021-04-26 |
2022-11-03 |
East Carolina University |
Compositions and methods of treating pathogenic infections by using fusion proteins
|
|
JP2024515803A
(ja)
|
2021-04-27 |
2024-04-10 |
ベイラー カレッジ オブ メディスン |
キメラ抗原受容体を発現するウイルス特異的免疫細胞
|
|
WO2022241029A1
(en)
|
2021-05-11 |
2022-11-17 |
Myeloid Therapeutics, Inc. |
Methods and compositions for genomic integration
|
|
TW202321443A
(zh)
|
2021-10-26 |
2023-06-01 |
新加坡商泰莎治療有限公司 |
用於生產編碼car之反轉錄病毒載體的細胞株
|
|
WO2023104910A1
(en)
|
2021-12-08 |
2023-06-15 |
Tessa Therapeutics Ltd. |
Treatment of lymphoma
|
|
JP2025513890A
(ja)
|
2022-04-13 |
2025-04-30 |
ティクヴァ アロセル プライベート リミテッド |
治療用ｔ細胞製品
|
|
CN119546338A
(zh)
|
2022-06-10 |
2025-02-28 |
研究发展基金会 |
经改造FcRIIB选择性IgG1 Fc变体及其用途
|
|
WO2024025343A1
(ko)
|
2022-07-26 |
2024-02-01 |
(주)에임드바이오 |
항-ror1 항체 및 이의 용도
|
|
CN117736299B
(zh)
*
|
2023-12-20 |
2025-12-19 |
杭州斯达特生物科技有限公司 |
重组人源CD8α蛋白及其制备方法与应用
|